FIELD: medicine.
SUBSTANCE: what is presented is a method for prediction of a high probability of the therapeutic effect of high-affinity anti-VEGF antibody, particularly ranibizumab in the patient with wet age-related macular degeneration (AMD). What is presented is a kit comprising a first oligonucleotide and second oligonucleotides specific for alleles of BATF gene polymorphism rs175714. If the genotype occurs to contain AA or AG, the high probability of the therapeutic effectiveness is predicted in the patient.
EFFECT: effective agents and methods for prediction of the high probability of the therapeutic effectiveness in the patients with wet AMD.
9 cl, 1 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETIC POLYMORPHISMS ACCOMPANYING AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2546008C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
| GENETIC MARKERS FOR PREDICTING RESPONSE TO THERAPY BY RAISING HDL LEVEL OR IMITATING HDL AGENTS | 2015 |
|
RU2703192C2 |
| GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY | 2014 |
|
RU2809215C2 |
| GENETIC MARKERS FOR PREDICTION OF SUSCEPTIBILITY TO THERAPY | 2014 |
|
RU2707533C2 |
| METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENOTYPE DEFINITION | 2005 |
|
RU2389798C2 |
| METHODS FOR SELECTIVE TREATMENT OF ASTHMA USING IL-13 ANTAGONISTS | 2015 |
|
RU2694980C2 |
| BIOMARKERS FOR ESTIMATING EFFICACY OF ALISKIREN AS HYPERTENSIVE AGENT | 2006 |
|
RU2408363C2 |
| HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENT AGENTS THAT TARGET TOXIN B CLOSTRIDIUM DIFFICILE | 2017 |
|
RU2761249C2 |
